ReShape Lifesciences Signs Exclusive License Agreement With Biorad Medisys For Obalon Gastric Balloon System
Portfolio Pulse from Happy Mohamed
ReShape Lifesciences Inc. (NASDAQ:RSLS) has signed an exclusive, royalty-bearing license agreement with Biorad Medysis to manufacture, commercialize and distribute the Obalon Gastric Balloon System in South Asia. The agreement includes an upfront payment of $200,000 from Biorad to ReShape and ongoing license payments of 4% on gross sales of the Obalon Balloon System in the territories.
September 21, 2023 | 12:32 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
The agreement with Biorad Medysis could potentially increase ReShape Lifesciences' revenue through upfront and ongoing license payments. This could also expand the company's market reach in South Asia.
The agreement with Biorad Medysis provides ReShape Lifesciences with an upfront payment and ongoing license payments, which could increase the company's revenue. Additionally, the partnership allows ReShape to expand its market reach in South Asia, potentially reaching 20% to 25% of the world's population. This could lead to increased sales and revenue in the future.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100